{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:23:15Z","timestamp":1793042595952,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Peritoneal dialysis-associated peritonitis (PDAP) is a frequent complication of peritoneal dialysis. The guidelines from the International Society for Peritoneal Dialysis (ISPD) suggest administering teicoplanin through the peritoneal route to treat PDAP, but do not specify the ideal concentration for peritoneal dialysis effluent (PDE). Patients meeting the trial criteria for PDAP in our hospital between July 2022 and December 2023 were enrolled. Data on PDE white blood cell count, PDE neutrophil percentage, clinical symptoms, CRP, and PCT were gathered pre- and post-treatment. Incidences of adverse drug reaction (ADR) and case numbers during treatment were recorded. Subsequently, patients were categorized into cured and uncured groups for evaluating the relationship between PDE teicoplanin concentration and treatment effectiveness. The self-control study results on teicoplanin efficacy indicated intraperitoneal teicoplanin administration achieved an efficacy rate of 88.9% and an ADR incidence of 5.5% in treating PDAP patients. There was no observed correlation between teicoplanin blood concentration and PDE concentration. PDE teicoplanin concentrations on days 1, 3, 5, and 7 post-dosing were higher inthe cured group, with a significant contrast in PDE concentration on day 5 between the 18.98 \u00b1 2.43\u00a0mg\/L of the cured group and the 12.07 \u00b1 2.68\u00a0mg\/L of the uncured group. ROC curve revealed a higher likelihood of cure in patients when PDE teicoplanin concentration exceeded 15.138\u00a0mg\/L on day 5 post-dosing. Univariate and multifactorial studies identified 24-h urine volume and the number of daily abdominal dialysis sessions as influential factors in PDE teicoplanin concentration on day 5. A positive correlation was found between 24-h urine volume and PDE teicoplanin concentration, with PDAP patients having urine volume over 537\u00a0mL showing significantly higher drug concentrations. Conversely, the number of daily PDAP sessions was negatively correlated with PDE teicoplanin concentrations, indicating that patients with 1\u223c3 daily PDAP sessions had notably higher PDE teicoplanin concentrations compared to those with 4\u223c6 sessions. Therefore, PDAP patients who use intraperitoneal teicoplanin could effectively control infection by monitoring the PDE teicoplanin concentration (&amp;gt;15.138\u00a0mg\/L) on day 5 after dosing.<\/jats:p>","DOI":"10.3389\/fphar.2024.1446774","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:52:36Z","timestamp":1725857556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["An investigation into the correlation between intraperitoneal teicoplanin concentrations and treatment outcomes in peritoneal dialysis-associated peritonitis"],"prefix":"10.3389","volume":"15","author":[{"given":"Lulu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/ndt\/gfm079","article-title":"Single UK centre experience on the treatment of PD peritonitis-antibiotic levels and outcomes","volume":"22","author":"Blunden","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2165\/00003088-198712040-00003","article-title":"Teicoplanin pharmacokinetics in patients with chronic-renal-failure","volume":"12","author":"Bonati","year":"1987","journal-title":"Clin. Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e02466-16","DOI":"10.1128\/AAC.02466-16","article-title":"Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy","volume":"61","author":"Byrne","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2015101169","article-title":"IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane","volume":"28","author":"Catar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B5","first-page":"319","article-title":"Foreign body reaction to dialysis chatheter and peritoneal fluid eosinophilia in a child on continuous ambulatory peritoneal dialysis","volume":"11","author":"Cetin","year":"2017","journal-title":"J. Kidney Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semnephrol.2016.10.008","article-title":"Peritoneal dialysis-related peritonitis: atypical and resistant organisms","volume":"37","author":"Cho","year":"2017","journal-title":"Semin. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/08968608221134980","article-title":"Predictors of serum vancomycin levels in peritoneal dialysis-associated peritonitis","volume":"43","author":"Deacon","year":"2023","journal-title":"PD Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3747\/pdi.2010.00294","article-title":"Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels","volume":"32","author":"Fish","year":"2012","journal-title":"Perit. Dial. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000336935","article-title":"Application of peritoneal dialysis in elderly patients by classifying the age into young-old, old, and oldest-old","volume":"177","author":"Hiramatsu","year":"2012","journal-title":"Contrib. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bcpt.13029","article-title":"Therapeutic drug monitoring of teicoplanin in haematological malignancy patients with febrile neutropenia and optimizing dosage regimens","volume":"123","author":"Hu","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3969\/j.issn.1009-6493.2010.10.006","article-title":"Analysis of related factors of patients accepting peritoneal dialysis","volume":"24","author":"Jin","year":"2010","journal-title":"Chin. Nurs. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9665","DOI":"10.2147\/IJN.S215717","article-title":"The clinical implication of vitamin D nanomedicine for peritoneal dialysis-related peritoneal damage","volume":"14","author":"Lee","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/08968608221080586","article-title":"ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment","volume":"42","author":"Li","year":"2022","journal-title":"Perit. Dial. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/21.suppl_a.123","article-title":"Efficacy and safety of teicoplanin in gram-positive peritonitis in patients on peritoneal dialysis","volume":"21","author":"Neville","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/21.suppl_a.123","article-title":"Efficacy and safety of teicoplanin in gram-positive peritonitis in patients on peritoneal-dialysis","volume":"21","author":"Neville","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jac\/dkg147","article-title":"Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose","volume":"51","author":"Pea","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the dali study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ndt\/gfaa350","article-title":"Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by 23-sodium magnetic resonance imaging","volume":"36","author":"Sahinoz","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s10096-016-2691-z","article-title":"Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction","volume":"35","author":"Ueda","year":"2016","journal-title":"Eur. J. Clin. Microbiol. and Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.16343\/j.cnki.issn.2095-512x.2017.02.005","article-title":"Efficacy analysis of intraperitoneal teicoplanin on treatment of peritoneal dialysis-related peritonitis","volume":"39","author":"Xu","year":"2017","journal-title":"J. Inn. Mong. Med. Univ."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1446774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:52:43Z","timestamp":1725857563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1446774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":20,"alternative-id":["10.3389\/fphar.2024.1446774"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1446774","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"article-number":"1446774"}}